Peptide History beginner
History of Peptide-GLP-1 Development
The journey from GLP-1 discovery to blockbuster diabetes and obesity drugs.
By Encyclopeptide Editorial | 1 min read
glp-1 incretin diabetes obesity
Overview
GLP-1 receptor agonists have become the most commercially successful peptide drug class, transforming diabetes and obesity treatment.
Key Milestones
- 1983: GLP-1 sequenced
- 1990s: Incretin hypothesis established
- 2002: Exendin-4 approved as exenatide
- 2010: Liraglutide approved
- 2017: Semaglutide approved
- 2019: Oral semaglutide breakthrough
- 2021: Semaglutide for obesity
- 2023: Tirzepatide dual agonist
Impact
GLP-1 agonists represent a paradigm shift in metabolic medicine, with potential benefits extending to cardiovascular, liver, and kidney diseases.
References
- Source: ENCP Peptide Database
- Category: Peptide History
Test Your Knowledge
Reinforce what you learned about History of Peptide-GLP-1 Development with interactive quizzes on Wikipept.
Take a Quiz on Wikipept